Here is the summary table, raw data from the pivotal trials
These breakthrough medications have taken the world by storm, offering hope for significant, sustainable weight management
The second drug, Zepbound, is FDA approved for weight loss and long-term weight management as well as for obstructive sleep apnea
Beyond-use date (BUD): The last date the medication should be used
Protocol 1: the gentle start (for GI-sensitive individuals) Goal: Minimize side effects completely while building to a therapeutic dose Best for: People with histories of medication sensitivity, IBS, acid reflux, or those who tried standard tirzepatide and could not tolerate it Complete schedule: Weeks 1-2: 0.125 mg weekly Weeks 3-4: 0.25 mg weekly Weeks 5-6: 0.5 mg weekly Weeks 7-8: 0.75 mg weekly Weeks 9-10: 1.0 mg weekly Weeks 11-14: 1.5 mg weekly Weeks 15-18: 2.0 mg weekly Weeks 19-22: 2.5 mg weekly Weeks 23-26: 5.0 mg weekly Time to therapeutic dose: 22-26 weeks Expected results: Minimal GI discomfort, gradual appetite reduction beginning around weeks 7-10, meaningful weight loss starting around weeks 15-18 This protocol takes nearly six months to reach 5 mg, but for someone who previously abandoned treatment due to side effects, six months on treatment beats three weeks of misery followed by quitting
Our personalized programs, including those featuring Mounjaro or Zepbound, are designed to take these physiological changes into account, offering medically supervised guidance every step of the way
